Cardiff Oncology, Inc. (CRDF) Misses Q4 EPS by 66c

Cardiff Oncology, Inc. (NASDAQ: CRDF) reported Q4 EPS of ($0.93), $0.66 worse than the analyst estimate of ($0.27). Revenue for the quarter came in at $480 thousand versus the consensus estimate of $50 thousand.

For earnings history and earnings-related data on Cardiff Oncology, Inc. (CRDF) click here.

You May Also Be Interested In

• Etsy upgraded to buy at BofA on durable growth, buyback potential
• JPMorgan Downgrades Rockwool (ROCKB:DC) (RKWBF) to Neutral
• ScanSource (SCSC) Tops Q4 EPS by 32c